All oral fixed-dose combination sofosbuvir/ledipasvir with or without ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: The phase 3 ION-1 study

Authors
Category Primary study
JournalGastroenterology
Year 2014
This article has no abstract
Epistemonikos ID: 3becbb1d454c0d694cb003f26bdf33608a54151d
First added on: Feb 06, 2025